Ensign Peak Advisors Inc Has $605,000 Stock Position in Sera Prognostics, Inc. (NASDAQ:SERA)

Ensign Peak Advisors Inc lowered its holdings in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 14.9% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 102,156 shares of the company’s stock after selling 17,844 shares during the period. Ensign Peak Advisors Inc owned about 0.31% of Sera Prognostics worth $605,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. StepStone Group LP acquired a new position in shares of Sera Prognostics during the 4th quarter worth $61,000. Lake Street Advisors Group LLC acquired a new position in shares of Sera Prognostics during the 2nd quarter worth $144,000. American Century Companies Inc. raised its holdings in shares of Sera Prognostics by 12.7% during the 2nd quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after buying an additional 2,891 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Sera Prognostics during the 2nd quarter worth $162,000. Finally, Sanders Morris Harris LLC acquired a new position in shares of Sera Prognostics during the 1st quarter worth $174,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Stock Performance

Sera Prognostics stock opened at $7.68 on Friday. Sera Prognostics, Inc. has a 52 week low of $1.56 and a 52 week high of $12.35. The stock has a fifty day moving average of $7.50 and a 200-day moving average of $8.17. The stock has a market capitalization of $256.28 million, a P/E ratio of -7.18 and a beta of 1.03.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 11,843.79%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.08 million. During the same period in the previous year, the company earned ($0.34) EPS. On average, research analysts forecast that Sera Prognostics, Inc. will post -0.95 earnings per share for the current year.

Insiders Place Their Bets

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 12,327 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total value of $91,466.34. Following the completion of the transaction, the chief executive officer now owns 856,918 shares of the company’s stock, valued at approximately $6,358,331.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Austin Aerts sold 5,056 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $7.57, for a total value of $38,273.92. Following the completion of the sale, the chief financial officer now owns 298,665 shares of the company’s stock, valued at $2,260,894.05. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Zhenya Lindgardt sold 12,327 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total value of $91,466.34. Following the completion of the sale, the chief executive officer now directly owns 856,918 shares of the company’s stock, valued at approximately $6,358,331.56. The disclosure for this sale can be found here. Insiders sold a total of 54,447 shares of company stock valued at $408,493 in the last 90 days. Corporate insiders own 15.80% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.